First New Essential Tremor Therapy in 50+ Years: Goldman Bullish on Praxis Precision
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
/ 8 items
#PRAX↓
Praxis Precision Medicines Wins FDA Breakthrough Status for Elsunersen in Rare Epilepsy
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
Wall Street Initiates Coverage on IMMX, PRAX & RNA with Buy Ratings – Morgan Stanley Downgrades ENGN
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.
Praxis Precision Medicines Shares Surge After FDA Accepts NDA for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines stock jumps as Food and Drug Administration reviews new tremor drug showing strong results and safety.
Ulixacaltamide Receives FDA Breakthrough Designation for Tremor Treatment
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for ulixacaltamide, a promising new treatment for essential tremor affecting 7 million Americans.
BTIG Boosts Praxis Precision Price Target, Calls It a Top Pick for 2026
BTIG raises its price target on Praxis Precision to $843, citing strong prospects for its essential tremor drug Ulixacaltamide and major growth potential ahead of 2026.